Pharmaceutical Research Peptide Therapeutics Market 2026 | Page 2

REPORT DESCRIPTION
Global Peptide Therapeutics Market – Global Industry Insights
The Global Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by
Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease,
Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral
Administration, and Others), was valued US$ 22.5 billion in 2018, and is projected to exhibit
a CAGR of 9.1% over the forecast period (2018 - 2026) as highlighted in a new report
published by Coherent Market Insights.
Request Sample: https://www.coherentmarketinsights.com/insight/request-sample/1837
Peptide therapeutics have wide range of applications in medicine and biotechnology and
therapeutic peptide research field. Peptide therapeutics are majorly used in the cancer
treatment and type 2 diabetes mellitus (T2DM) treatment. According to the Drug Discovery
Today, January 2015 data findings, novel peptide drug class: glucagon-like peptide-1 (GLP-1)
agonists; indicated for the treatment of type 2 diabetes mellitus (T2DM), shows lucrative
market growth, as Victoza from Novo Nordisk, is the most prominent member of the class,
reaching blockbuster status. Moreover, main area currently driving the growth of peptide
therapeutics drugs adoption are metabolic diseases and cancer treatment. Furthermore,
peptide therapeutics are in clinical testing for infectious diseases and inflammation.
© Coherent market Insights. All Rights Reserved